Gestational diabetes & diabetes in pregnancy
Unintentional periconceptional exposure to glucagon‐like peptide‐1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan
Authors' conclusion
Periconceptional GLP-1 RA exposure was not associated with increased risks of malformations, stillbirth, preterm birth or SGA versus insulin use. These preliminary data require confirmation in larger agent-specific studies; until then, intentional GLP-1 RA use in planned pregnancy is not advised.
Study context
- Population
- Singleton births to mothers (18–50 years) with pregestational diabetes, Taiwan Birth Certificate Application and National Health Insurance claims (2013–2022)matched 160 vs 606
- Participants
- 3,351 births
- Exposure
- Periconceptional GLP-1 RA exposure vs insulin without GLP-1 RA
- GLP-1 RAn = 160
- Insulinn = 606reference
- Outcome
- Major congenital malformations, stillbirth, preterm birth (<37 weeks) and small for gestational age (SGA) (<10th percentile)
Methodological details1:4 propensity-score matching, active comparator, Poisson generalised estimating equation
- 1:4 propensity-score matching
- Active comparator
- Poisson generalised estimating equation
Main finding
As reported in the abstract
Adverse pregnancy outcomes
GLP-1 RA vs InsulinRelative risk (95% CI)
Malformations
0.64(0.11–3.83)
Stillbirth
2.05(0.82–5.13)
Preterm birth
1.09(0.85–1.39)
SGA
0.86(0.31–2.41)
Observational data: associations, not effects.
Further findings
Sensitivity analyses (≥2 prescriptions; first-trimester exposure)
- Sensitivity analyses were similar
Original publication
Unintentional periconceptional exposure to glucagon‐like peptide‐1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan. Diabetes Obes Metab. Published 5 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →